Last reviewed 2026-04-23 · How we verify

Amivantamab SC

Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.

Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors. Used for Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation, Locally advanced or metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation.

At a glance

Mechanism of action

By binding to these receptors, amivantamab SC inhibits the signaling pathways that promote tumor growth and survival. This mechanism of action is thought to contribute to its therapeutic effects in patients with non-small cell lung cancer.

Approved indications

• Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation
• Locally advanced or metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation

Common side effects

• Interstitial lung disease
• Pneumonitis
• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (PHASE2)
• A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer (PHASE1, PHASE2)
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
• A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PHASE1)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
• Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer (PHASE2)
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.